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MOLECULAR DIAGNOSIS OF HUNTINGTON
DISEASE IN BRAZILIAN PATIENTS
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ABSTRACT - Huntington disease (HD) is a progressive neurodegenerative disorder with autosomal dominant
inheritance, characterized by choreiform movements and cognitive impairment. Onset of symptoms is around 40
years of age and progression to death occurs in approximately 10 to 15 years from the time of disease onset. HD
is associated with an unstable CAG repeat expansion at the 5’ and of the IT15 gene. We have genotyped the CAG
repeat in the IT15 gene in 44 Brazilian individuals (42 patients and 2 unaffected family members) belonging to
34 unrelated families thought to segregate HD. We found one expanded CAG allele in 32 individuals (76%)
belonging to 25 unrelated families. In these HD patients, expanded alleles varied from 43 to 73 CAG units and
normal alleles varied from 18 to 26 CAGs. A significant negative correlation between age at onset of symptoms
and size of the expanded CAG allele was found (r=0.6; p=0.0001); however, the size of the expanded CAG
repeat could explain only about 40% of the variability in age at onset (r2=0.4). In addition, we genotyped 25
unrelated control individuals (total of 50 alleles) and found normal CAG repeats varying from 16 to 33 units. The
percentage of heterozigocity of the normal allele in the control population was 88%. In conclusion, our results
showed that not all patients with the “HD” phenotype carried the expansion at the IT15 gene. Furthermore,
molecular diagnosis was possible in all individuals, since no alleles of intermediate size were found. Therefore,
molecular confirmation of the clinical diagnosis in HD should be sought in all suspected patients, making it
possible for adequate genetic counseling.
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Diagnóstico molecular da doença de Huntington em pacientes brasileiros
RESUMO - A doença de Huntington (HD) é afecção neurodegenerativa com padrão de herança autossômica
dominante caracterizada por movimentos involuntários coreiformes e alterações cognitivas. O início dos sintomas
ocorre em torno dos 40 de idade, progredindo até a morte em um período de aproximadamente 10 a 15 anos após
o início da doença. A HD está associada a uma expansão trinucleotídica CAG presente na porção 5’ do gene
IT15. Nós investigamos a repetição CAG no gene IT15 em 44 indivíduos brasileiros (42 pacientes e 2 membros
não afetados de uma família) pertencentes a 34 famílias não relacionadas com diagnóstico provável de HD. Um
alelo CAG expandido foi encontrado em 32 indivíduos (76%) pertencentes a 25 famílias não relacionadas. Nos
pacientes com a mutação HD, os alelos expandidos variaram de 43 a 73 unidades de repetição CAG e os alelos
normais apresentaram variação de 18 a 26 CAGs. Correlação negativa significativa foi encontrada entre a idade
de início dos sintomas e o tamanho da expansão trinucleotídica CAG (r=0,6; p=0,0001); no entanto, o tamanho
da repetição CAG expandida foi capaz de explicar somente 40% da variação encontrada na idade de início da
doença (r2=0,4). Além disso, nós genotipamos um total de 25 indivíduos pertencentes a um grupo controle da
população brasileira (total de 50 alelos), sendo que o alelo normal apresentou variação de 16 a 33 unidades de
repetição CAG. A porcentagem de heterozigozidade do alelo normal na população brasileira controle foi 88%.
Em conclusão, nossos resultados mostraram que nem todos os pacientes com fenótipo ‘‘HD’’ possuíam a expansão
CAG no gene IT15. O diagnóstico molecular foi possível em todos os indivíduos analisados nesse estudo, não
sendo encontrada em nossa amostra nenhum alelo de tamanho intermediário. Portanto, nós recomendamos que a
confirmação molecular do diagnóstico na HD deva ser realizada em todos os casos suspeitos, a fim de proporcionar
subsídios para um aconselhamento genético adequado.
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Huntington disease (HD) is a progressive adult-onset neurodegenerative disorder presenting
an autosomal dominant inheritance1-3. Onset of symptoms occurs usually in the fourth decade of
life; however, it may vary from 4 to 80 years of age1-3. Prevalence of the disease is variable according
to ethnic background, in Caucasians of North America and Europe it is believed to affect between 5
to 10 in 100 000 population1-3. HD is clinically characterized by involuntary choreiform movements,
cognitive impairment, and personality disorder tending to depression, anger and temper outbursts2,3.
Neuronal degeneration is seen in several regions of the central nervous system, but is more evident
in the caudate and the putamen of the basal ganglia2-4.
The HD gene was genetically linked to an anonymous DNA marker located in chromosome (ch)
4p16.35. After a decade of research the gene causing the disease, the IT15 gene, was identified by
positional cloning techniques6. The mutation causing HD was characterized as the expansion of an
unstable CAG trinucleotide repeat localized in the first exon of the IT15 gene6. Studies in a large
number of individuals of different ethnic origins have shown that normal alleles carry 6 to 34 CAG
units; whereas, HD alleles have more than 40 CAG units7-10. It has been demonstrated that both normal
and expanded CAG tracts encode a polyglutamine stretch within the protein named huntingtin11,12.
Huntingtin is a 350 kDa cytoplasmatic protein, widely expressed which has unknown function13.
Unstable expansions of CAG tracts have been found in a growing number of autosomal
dominant degenerative disorders, including Kennedy disease14 and six types of autosomal dominant
spinocerebellar ataxias (SCAs): SCA1, SCA2, MJD/SCA3, SCA6, SCA7 and DRPLA15. The exact
mechanism by which expansions of CAG repeats cause disease is not understood; however, evidence
points to a mechanism involving gain of function by the genes involved16-18.
We have genotyped the CAG trinucleotide repeat in the IT15 gene in Brazilian patients and
control subjects in order to: a) confirm the presumptive clinical diagnosis of HD in our group of patients,
b) compare the size range of the CAG repeat in the HD and control population, and c) investigate the
relationship between the size of the expanded CAG allele and age at onset of the disease.
SUBJECTS
This study was performed using DNA samples, obtained after informed consent, from 44
family members, including 42 clinically affected individuals belonging to 34 unrelated families, 16
males and 28 females. Forty-two of these individuals presented with dementia and /or involuntary
movements and received the presumptive clinical diagnosis of HD. There were two unaffected
individuals belonging to one family from which a patient was also available for genotyping. Ages at
onset varied from 12 to 58 years, mean of 39 years. Families were ascertained in four University
based clinical centers in the southern and southeastern regions of Brazil: São Paulo, Rio de Janeiro
and Paraná. Ages at onset were based on information provided by the patient and/or a close relative.
For determination of the frequency of the normal alleles we used 50 normal chromosomes identified
in 25 unrelated control individuals of the Brazilian population. This project was approved by the
Ethics Committee of the Faculdade de Ciências Médicas - UNICAMP.
METHOD
Genomic DNA was isolated from peripheral lymphocyte by standard methods19. PCR amplification of
the CAG repeat in the IT15 gene was performed with primers HD1 and HD36,20, which are adjacent to the CAG
stretch6,20,21 PCR reactions were performed in a total volume of 12.5µl containing 100ng of genomic DNA; 1.6
mM of each dNTP (dATP, dCTP, dGTP, dTTP ); 4 pmol of each primer; 5% DMSO; 0.2 U Perfect Match
(Stratagene) and 0.5 units Taq DNA polimerase. After an initial denaturation of 2 min at 95°C the amplification
was accomplished in 30 cycles at the following temperatures: denaturing at 94°C for 1 min, annealing at 50°C for
1 min, and extension at 72°C for 2 min, followed by a final extension at 72 °C for 7 min. PCR products were
separated by electrophoreses through a 6% denaturing polyacrylamide gel. Gels were transferred into Hybond
N+ nylon membranes and hybridized with a α-32P 3'-end labeled (CAG)15 probe22. Allele sizes were determined
by comparing migration relative to a sequencing ladder (Fig 1). Alleles were considered normal when less than
35 CAGs and expanded when they contained more than 40 CAGs23.
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We used linear regression analysis to determine the association between repeat number in the HD or
normal alleles and age at onset. We assessed differences in repeat number among males, females, maternal and
paternal transmissions by analysis of variance. All statistical analyses were accomplished by using the computer
program SYSTAT24.
RESULTS
We identified 32 individuals, belonging to 25 families, with one expanded CAG allele at the
IT15 gene. Two of these individuals were considered to be unaffected at the time of clinical evaluation,
but had affected relatives who were also genotyped in our study. (Table). The frequency of the HD
mutation in our group of patients was 76% (32/42). Expanded alleles varied from 43 to 73 CAG
repeats (mean = 50.6 CAG units) and normal alleles in HD patients varied from 18 to 26 CAG units
(mean = 22 CAGs) (Fig 2). There was no significant difference in the size of the expanded alleles
between affected males (mean = 49.7) and affected females (mean = 52.3); p = 0.7.
Autosomal dominant inheritance could be documented in all but 3 patients who had no family
history of the disease. Transmission of the disease was paternal in 18 cases and maternal in 11
patients. There was no significant difference in the size of the expanded CAG repeat between patients
with paternal (mean = 51.6 CAG units) and maternal transmission (mean = 51.5 CAGs); p = 1.00.
The relationship between the CAG repeat length in the HD allele of affected individuals and
age at onset of the disease is shown in Figure 3A. A correlation coefficient of – 0.6 was obtained
(r2=0.4; p=0.0001), assuming a linear relationship between age at onset and repeat length in HD chs.
Fig 1. Analysis of PCR products
containing the expanded CAG repeat
at the HD locus. Genomic DNA was
amplified using primers HD1 e HD3
(ref.20). PCR products were analysed
on 6% polyacrylamide gels. Allele
sizes were determined by comparison
with a sequencing ladder. Normal
alleles (NA) had sizes varying from
19 to 26 CAG units and expanded
alleles (EA) varied from 43 to 73
CAGs.
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Table. Demographic data and molecular characteristics of 32 individuals segregating the HD mutation.
ID Family Sex Transmission Onset Expanded Normal
 (years) Allele Allele
(CAG units) (CAG units)
01 HD1 Male Paternal 38 52 20
02 HD1 Male Paternal 40 49 19
03 HD2 Female Paternal 26 55 19
04 HD3 Male Paternal 40 47 22
05 HD3 Male Paternal 26 48 23
06 HD4 Female Maternal 12 72 22
07 HD5 Male Maternal 58 43 22
08 HD6 Female Maternal 26 52 26
09 HD7 Female Maternal 37 47 22
10 HD8 Female Maternal 32 48 18
11 HD10 Male Isolated 22 45 21
12 HD11 Female Isolated 20 54 26
13 HD12 Male Paternal 25 45 20
14 HD13 Female Maternal 29 52 20
15 HD14 Male Paternal 38 46 26
16 HD14 Male Paternal 39 50 26
17 HD20 Male Paternal 32 53 26
18 HD22 Male Maternal 30 54 20
19 HD24 Female Paternal 53 50 25
20 HD24 Female Paternal 34 49 25
21 HD25 Female Isolated 54 43 20
22 HD26 Female Paternal 53 46 25
23 HD26 Female Maternal U* 46 25
24 HD26 Female Maternal U* 49 26
25 HD27 Male Paternal 42 52 20
26 HD28 Female Paternal 50 50 19
27 HD29 Female Paternal 40 53 20
28 HD29 Male Paternal 14 54 20
29 HD30 Female Maternal 34 58 25
30 HD31 Male Paternal 25 58 20
31 HD33 Female Paternal 16 73 20
32 HD34 Female Maternal 32 46 20
*U, unaffected individual
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Fig 2. Frequency distribution of the CAG repeat sizes in controls and HD individuals. A) Distribution of
50 normal alleles genotyped in 25 unrelated control individuals of the Brazilian population. B) Distribution
of 32 expanded alleles found in 25 unrelated Brazilian HD families.
No significant correlation was found between the normal CAG allele and age at onset (r = 0.09, r2 =
0.008, p=0.6). (Figure 3B).
In the 25 individuals of the control group (total of 50 alleles) we found normal CAG repeats
varying from 16 to 33 CAG units; with 88% of control subjects being heterozygous for the CAG
repeat in the IT15 gene. No expanded alleles were found in the control population.
DISCUSSION
With the cloning of the HD gene in 19936 and characterization of the causative mutation, an
accurate diagnosis can now be performed, even in small families or single affected individuals. This
results in a better estimate of the prevalence of HD, as well as provide more detailed clinical, pathological
and molecular information that will improve our understanding of this disorder25. The same type of
unstable expansion of a CAG tract has been found in other degenerative disorders and that the function
of most genes involved in these diseases is still unknown15-17. However, recent evidence from protein
studies and transgenic animal models suggest a toxic gain of function by the proteins containing an
expanded glutamine tract11-13,18. Polyglutamine expansions in specific proteins, are one of the most
intriguing pathological mechanisms causing adult-onset neurodegenerative disorders. While the normal
gene product tolerate a wide variation in size of a polyglutamine tract, beyond a threshold the proteins
Fig 3. A) Correlation of CAG repeat length in HD chromosomes of 30 affected individuals with
age at onset of the disease (Pearson correlation coefficient (r) = - 0.6; r2 = 0,4; p=0,0001). B)
Absence of correlation between age at onset and CAG repeat length in the normal chromosomes
of 30 affected individuals (r = 0.09; r2= 0.008; p=0.6).
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acquire pathogenic properties16. The selective neuronal death that occur in all of these disorders, shows
no correlation with the pattern of expression of the corresponding proteins. Since they are widely
expressed in the central nervous system and peripheral tissue11-13. During the past two years research
has moved towards studying the possible mechanisms by which expanded polyglutamine tracts cause
neurodegeneration11,18. It is a very exciting new field of investigation, requiring molecular biology
combined with cell biology tools; this will certainly provide important advances in the understanding
of the mechanisms underlying neuronal death. The progress in basic research will in turn provide
options for better treatment of patients suffering from these devastating disorders.
To our knowledge, this is the first study reporting molecular testing of HD patients in the
Brazilian population. Analysis of the CAG repeat in the IT15 gene in Brazilian families confirmed
the presence of the expanded CAG repeat in 76% of patients with the presumptive diagnosis of HD.
The size range of the expanded and normal alleles found in our study was similar to that reported in
the literature6-10,23 and no intermediate alleles, between 35 and 40 CAGs23,26,27, were found. Therefore,
accurate molecular diagnosis was possible in all individuals. In addition, the high heterozygocity
observed for the normal CAG tract in the Brazilian population (88%) reduces the probability of
finding individuals that are homozigous for the normal CAG allele. Individuals homozigous for the
CAG allele in the normal range may be difficult to differentiate from failure to amplify an expanded
allele in the PCR assay23.
Differences in the stability of the CAG tract according to sex of transmitting parent have been
reported7-10,28, with male transmissions being more unstable and with a tendency for further expansions
of the abnormal CAG tract7,28. Although we could not document any transmission of the expanded
CAG in this study, our results did not show any differences in the distribution of CAG alleles among
groups according to gender of transmitting parent.
There are several well documented de novo mutations in sporadic HD patients which have
been reported in the literature7,29-31. We identified three patients with no family history of the disease
who were found to have the HD mutation. However, in all three instances clinical information on
the parents could not be accurately obtained, since they either died at a very young age or were not
available for examination. Therefore, it seems more likely that in these three families autosomal
dominant transmission was not documented due to missing information. However, the possibility
that in these patients the CAG repeat in the IT15 gene could have undergone a new mutation event
cannot be completely excluded.
We found a significant correlation between age at onset of the disease and length of the
expanded CAG tract. This indicates a tendency for age at onset to decrease as the CAG repeat length
increases. Overall, 40 % of variability in age at onset could be accounted for by the size of the CAG
tract. However, our data (Table) together with reports in the literature6,32,33 suggest that any given
expanded CAG repeat is associated with a broad range of onset ages, highlighting the importance of
other factors in determining age at onset. The most frequent found expanded allele in our study was
52 CAG repeats, which was associated with ages at onset varying from 26 to 42 years. Therefore,
predictions of age at onset based on expanded CAG repeat sizes should not be used as indicator of
age at onset in individuals patients.
In conclusion, our results showed that not all patients with the “HD” phenotype carried the
expansion at the IT15 gene and that autosomal dominant inheritance may not be clearly documented
in all HD families. Therefore, molecular confirmation of the clinical diagnosis should be sought in
all patients with suspected HD, even in apparently isolated cases. However, it is important to
emphasize that a multidisciplinary, counseling and supportive group should always be available for
patients undergoing molecular testing34-36.
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